April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer Subset
November 30th 2022The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.
89Zr-DFO-Girentuximab PET Agent Meets Specificity and Sensitivity End Points in Clear Cell RCC
November 8th 2022The investigational imaging agent 89ZR-DFO-girentuximab met all primary and secondary end points, exceeding pre-determined sensitivity and specificity targets in clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.
Pembrolizumab Plus Lenvatinib May Serve as Potential Frontline Treatment for Non–Clear Cell RCC
October 5th 2022Patients with locally advanced/metastatic non–clear cell renal cell carcinoma experienced promising preliminary antitumor activity following treatment with pembrolizumab and lenvatinib in the first line.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 2nd 2022Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Antitumor Activity Noted With Pembrolizumab Plus Lenvatinib in Frontline Non–Clear Cell RCC
September 13th 2022Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with a combination of pembrolizumab and lenvatinib in the frontline treatment of non–clear cell renal cell carcinoma.
Efficacy Persists with Lenvatinib Plus Pembrolizumab Vs Sunitinib in Advanced Clear Cell RCC
September 11th 2022Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.
Cabozantinib Combination Yields Improvement in PFS for Advanced RCC
July 12th 2022The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.